These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 14664904)

  • 1. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA.
    Lentz SR; Rodionov RN; Dayal S
    Atheroscler Suppl; 2003 Dec; 4(4):61-5. PubMed ID: 14664904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADMA and hyperhomocysteinemia.
    Dayal S; Lentz SR
    Vasc Med; 2005 Jul; 10 Suppl 1():S27-33. PubMed ID: 16444866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.
    Sydow K; Hornig B; Arakawa N; Bode-Böger SM; Tsikas D; Münzel T; Böger RH
    Vasc Med; 2004 May; 9(2):93-101. PubMed ID: 15521698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase.
    Böger RH; Vallance P; Cooke JP
    Atheroscler Suppl; 2003 Dec; 4(4):1-3. PubMed ID: 14664896
    [No Abstract]   [Full Text] [Related]  

  • 5. ADMA and oxidative stress.
    Sydow K; Münzel T
    Atheroscler Suppl; 2003 Dec; 4(4):41-51. PubMed ID: 14664902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
    Böger RH; Bode-Böger SM; Sydow K; Heistad DD; Lentz SR
    Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1557-64. PubMed ID: 10845872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction.
    Stühlinger MC; Stanger O
    Curr Drug Metab; 2005 Feb; 6(1):3-14. PubMed ID: 15720202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma asymmetric and symmetric dimethylarginine in a rat model of endothelial dysfunction induced by acute hyperhomocysteinemia.
    Magné J; Huneau JF; Borderie D; Mathé V; Bos C; Mariotti F
    Amino Acids; 2015 Sep; 47(9):1975-82. PubMed ID: 25792109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease.
    Böger RH; Zoccali C
    Atheroscler Suppl; 2003 Dec; 4(4):23-8. PubMed ID: 14664899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.
    Ueda S; Yamagishi SI; Matsumoto Y; Fukami K; Okuda S
    Clin Exp Nephrol; 2007 Jun; 11(2):115-121. PubMed ID: 17593510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of asymmetric dimethylarginine and endothelial dysfunction.
    Böger RH
    Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes.
    Tsikas D; Bollenbach A; Hanff E; Kayacelebi AA
    Cardiovasc Diabetol; 2018 Jan; 17(1):1. PubMed ID: 29301528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
    Siroká R; Cibulka R; Rajdl D; Racek J
    Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule.
    De Gennaro Colonna V; Bianchi M; Pascale V; Ferrario P; Morelli F; Pascale W; Tomasoni L; Turiel M
    Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Methylarginies-induced endothelial dysfunction in chronic kidney disease].
    Kimura K
    Yakugaku Zasshi; 2012; 132(4):443-8. PubMed ID: 22465920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
    Maas R
    Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymmetric dimethylarginine in adults with cystathionine β-synthase deficiency.
    Rocha MS; Teerlink T; Janssen MC; Kluijtmans LA; Smulders Y; Jakobs C; Tavares de Almeida I; Rivera I; Castro R; Blom HJ
    Atherosclerosis; 2012 Jun; 222(2):509-11. PubMed ID: 22484094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine.
    Stühlinger MC; Tsao PS; Her JH; Kimoto M; Balint RF; Cooke JP
    Circulation; 2001 Nov; 104(21):2569-75. PubMed ID: 11714652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial cell dysfunction: the syndrome in making.
    O'Riordan E; Chen J; Brodsky SV; Smirnova I; Li H; Goligorsky MS
    Kidney Int; 2005 May; 67(5):1654-8. PubMed ID: 15840005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Asymmetric dimethyl arginine (ADMA): a novel cardiovascular risk factor?].
    Stühlinger M
    Wien Med Wochenschr; 2007 Feb; 157(3-4):57-60. PubMed ID: 17340060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.